GlassScriptPhysician profile
Erick O Calmet Del Castillo
NPI 1447401716
$3,713.32
in general payments reported to CMS, 2019-2025
37 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $621 · 2021: $755 · 2022: $421 · 2023: $316 · 2024: $221 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.77 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $473.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $360.59 | 2019-2025 | |
| Amgen INC. | $256.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $251.02 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $222.66 | 2020-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $167.09 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.87 | 2025 | Caplyta |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Verona Pharma, INC. | $76.40 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.42 | 2019-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $56.76 | 2019 | |
| Daiichi Sankyo INC. | $54.81 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $53.82 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $48.62 | 2021-2025 | Trintellix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Calmet Del Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.